Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7 Tumor-Agnostic 4 Gynecologic 3 Lymphoid 2 Head & Neck 2 Genitourinary 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 NET 1 Endocrine 1 CNS 1 Breast 1

Conditions

Intestinal Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 15 Magnetic Resonance Spectroscopy 9 Everolimus 8 gallium Ga 68 dotatate 6 lanreotide 4 cabozantinib 4 Temozolomide 4 Specimen Handling 4 Nivolumab 4 Lutetium-177 4 Lutetium 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 surufatinib 3 olaparib 3 copper dotatate CU-64 3 Somatostatin 3 Injections 3 Ga(III)-DOTATOC 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Capecitabine 3 pembrolizumab 2 fludarabine phosphate 2 fludarabine 2 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Sunitinib 2 Radiosurgery 2 Octreotide 2 Drug Therapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Data Collection × NET × Clear all

NCT06876532 2025-11-18

LUTIBI

Institut Claudius Regaud

Phase NA Recruiting

Intestinal Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡